Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins

Witkiewicz, Agnieszka K.; McConnell, Thomas G.; Potoczek, Magdalena; Emmons, Robert; Kurman, Robert J.

doi:10.1016/j.humpath.2009.06.012

Cited by 30 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, they are the targets of many immunotherapy protocols [10]. Also, its presence in the tumor stroma has been associated with prognosis in several carcinomas including ovarian, colon and EEC [11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas

et al. 2016

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas

et al. 2016

View full text Add to dashboard Cite

“…This arrangement of cells in the peritumorous zone contradicts the idea of direct interaction of NK cells with malignancy. 11,13,14 Moreover, experimental data by Spano and Zollo 15 revealed a tumor-associated functional defectiveness of NK cells, probably caused by tumor-associated cytokines.…”

Section: Discussionmentioning

confidence: 99%

Tumor-Infiltrated Lymphocytes, Macrophages, and Dendritic Cells in Endometrioid Adenocarcinoma of Corpus Uteri as Potential Prognostic Factors: An Immunohistochemical Study

Зиновкин

Pranjol

2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

In conclusion, our study showed for the first time that the low level of expression of markers for tumor-associated T lymphocytes (CD3), NK cells (CD57), macrophages (CD68), and an increased expression of markers for tumor-associated B lymphocytes (CD20) and dendritic cells (S100) in endometrioid adenocarcinoma progression lead to poor survival outcome. The associated criteria of these immune cells may be used as predictive factors in the diagnosis of tumor progression. Our study indicates that local antitumor immune response may be applied to define risk groups to predict clinical outcomes.

show abstract

“…Treatment time no <6 months to accurately assess response, was also recommended by Gunderson and colleagues in a recent review of women receiving progestin therapy for atypical endometrial hyperplasia. However, when meta‐analyses of studies are evaluated the results are less comparable because of variation in type, dose, regimen and duration of oral treatment …”

Section: Discussionmentioning

confidence: 99%

Levonorgestrel‐impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial

Ørbo

Vereide

Arnes

et al. 2013

BJOG

110

101

View full text Add to dashboard Cite

ObjectiveThe purpose of this study was to investigate if the levonorgestrel-impregnated intrauterine device (LNG-IUS, Mirena®) is safe and effective as therapy for low-risk and medium-risk endometrial hyperplasia compared with oral medroxyprogesterone (MPA).DesignA multicentre randomised trial.SettingNorway.PopulationIn all, 170 women aged 30–70 years with low- or medium-risk endometrial hyperplasia who met inclusion criteria.MethodsPatients were randomly assigned to one of three treatment arms: LNG-IUS; oral MPA 10 mg administered for 10 days per cycle, or continuous oral MPA 10 mg daily, for 6 months.Main outcome measuresThe primary outcome measure was normalisation or persisting hyperplasia.ResultsAfter 6 months all three treatment regimens showed significant effect when the outcome was evaluated as therapy response or not (P < 0.001). Responses were obtained for all the women in the LNG-IUS group (53/53, 95% CI 0.93–1.0) and for 96% of the women in the continuous oral group (46/48, 95% CI 0.86–0.99). Only 69% of the women in the cyclic oral group were responders (36/52, 95% CI 0.55–0.81). Adverse effects were relatively common with minimal differences between therapy groups.ConclusionIn the first trial of its kind, women treated with the LNG-IUS showed histologically normal endometrium after 6 months of therapy for endometrial hyperplasia. Cyclical progestogens are found to be less effective compared with continuous oral therapy and LNG-IUS and should not be used for this purpose.

show abstract

Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins

Cited by 30 publications

References 36 publications

CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas

CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas

Tumor-Infiltrated Lymphocytes, Macrophages, and Dendritic Cells in Endometrioid Adenocarcinoma of Corpus Uteri as Potential Prognostic Factors: An Immunohistochemical Study

Levonorgestrel‐impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial

Contact Info

Product

Resources

About